Home > Insider Trading > Filing (0001127602-25-009283)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
882095	Gilead Sciences Inc.	GILD	Biological Products, (No Disgnostic Substances) (2836)	943047598

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1310204	D Andrew Dickinson	Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-03-10	4,916	$63.91	173,977	No	4	M	Direct
Common Stock	Acquisiton	2025-03-10	13,013	$63.91	186,990	No	4	M	Direct
Common Stock	Disposition	2025-03-10	4,916	$117.30	182,074	No	4	S	Direct
Common Stock	Disposition	2025-03-10	13,013	$118.50	169,061	No	4	S	Direct
Common Stock	Acquisiton	2025-03-10	7,968	$0.00	177,029	No	4	M	Direct
Common Stock	Disposition	2025-03-10	3,855	$117.21	173,174	No	4	F	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	F	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-qualified Stock Option (Right to Buy)	Disposition	2025-03-10	4,916	$0.00	4,916	$63.91
Common Stock	Non-qualified Stock Option (Right to Buy)	Disposition	2025-03-10	13,013	$0.00	13,013	$63.91
Common Stock	Restricted Stock Unit	Disposition	2025-03-10	7,968	$0.00	7,968	$0.00
Common Stock	Non-qualified Stock Option (Right to Buy)	Acquisiton	2025-03-10	49,020	$0.00	49,020	$117.21
Common Stock	Restricted Stock Unit	Acquisiton	2025-03-10	11,090	$0.00	11,090	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
13,013	2031-03-10	No	4	M	Direct
0	2031-03-10	No	4	M	Direct
27,519		No	4	M	Direct
49,020	2035-03-10	No	4	A	Direct
38,609		No	4	A	Direct

Footnotes

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
Sale prices reported for the transactions reported here range from $116.97 to $117.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Sale prices reported for the transactions reported here range from $118.00 to $118.80. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.